Edison healthcare quarterly: Crisis? What crisis?
The book opens with an overview from Franc Gregori. He writes that the Q2 reporting season produced no nasty surprises but did highlight the (still) rising pressures facing the pharmaceutical industry. Yet we believe the worst will soon be over, with the five-year earnings outlook set to improve. He believes that from an investment perspective there are clear opportunities, especially within the smaller companies’ universe, and we re-iterate our view that stock selection remains the key.Download PDF